Lessons Learned From Major Clinical Outcomes Trials Involving Sodium–Glucose Cotransporter 2 Inhibitors

Abstract

Diabetes is a known risk factor for the development of cardiovascular and chronic kidney disease. Sodium– glucose cotransporter 2 inhibitors are glucose-lowering medications that have been demonstrated to improve clinical cardiovascular and renal outcomes. This article reviews recent large clinical trials involving these medications and explains their impact on type 2 diabetes treatment guidelines.